MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Clinical trial NCT02407405 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02407405
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Neurofibromatosis 1 (NF1)Plexiform Neurofibromas (PN)

Start date: 2016-01-07
Primary completion: 2028-01-01
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.